Literature DB >> 27163640

Different effects of GPR120 and GPR40 on cellular functions stimulated by 12-O-tetradecanoylphorbol-13-acetate in melanoma cells.

Kaori Fukushima1, Kaede Takahashi1, Nobuyuki Fukushima2, Kanya Honoki3, Toshifumi Tsujiuchi4.   

Abstract

G-protein-coupled receptor 120 (GPR120) and GPR40 exhibit a variety of biological responses by the binding of free fatty acids. 12-O-Tetradecanoylphorbol-13-acetate (TPA) is a tumor promoting agent of skin carcinogenesis. It is known that TPA treatment stimulates cell motile activity of cancer cells, including melanoma cells. In the present study, we investigated whether GRP120 and GPR40 are involved in regulation of cell motile activity induced by TPA in two melanoma cell lines. A375 and G361 cells were treated with TPA at a concentration of 10 nM for 24 h. The cell motile activity of A375 cells was significantly increased by TPA, correlating with GPR40 expression. In contrast, TPA suppressed the cell motile activity of G361 cells, while GPR120 and GPR40 expressions were increased. The cell motile activity of A375 cells treated with TPA was markedly increased by GPR120 knockdown. In addition, to assess roles of GPR120 and GPR40 in cellular functions of A375 cells by the long-term TPA treatment, cells were treated with TPA (1 nM) for at least 3 months. The long-term TPA treatment induced the high cell motile activity and elevated GPR120 and GPR40 expressions. The high cell motile activity of A375 cells stimulated by the long-term TPA treatment was enhanced by GPR120 knockdown. These results suggest that GPR120 negatively and GPR40 positively regulate cell motile activities induce by TPA in melanoma cells.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell motility; GPR120; GPR40; Melanoma cells; TPA

Mesh:

Substances:

Year:  2016        PMID: 27163640     DOI: 10.1016/j.bbrc.2016.05.023

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Pelargonidin reduces the TPA induced transformation of mouse epidermal cells -potential involvement of Nrf2 promoter demethylation.

Authors:  Shanyi Li; Wenji Li; Chao Wang; Renyi Wu; Ran Yin; Hsiao-Chen Kuo; Lujing Wang; Ah-Ng Kong
Journal:  Chem Biol Interact       Date:  2019-06-07       Impact factor: 5.192

2.  Serum Free Fatty Acids and G-Coupled Protein Receptors Are Associated With the Prognosis of Epithelial Ovarian Cancer.

Authors:  Lili Zhang; Xiangzhong Zhao; Huijun Chu; Han Zhao; Xiaoying Lai; Jing Li; Teng Lv
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

Review 3.  The role of free-fatty acid receptor-4 (FFA4) in human cancers and cancer cell lines.

Authors:  Ilya S Senatorov; Nader H Moniri
Journal:  Biochem Pharmacol       Date:  2018-02-13       Impact factor: 5.858

4.  GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery.

Authors:  Gabriele Carullo; Sarah Mazzotta; Margarita Vega-Holm; Fernando Iglesias-Guerra; José Manuel Vega-Pérez; Francesca Aiello; Antonella Brizzi
Journal:  J Med Chem       Date:  2021-04-10       Impact factor: 7.446

5.  12-O-Tetradecanoylphorbol-13-acetate (TPA) is anti-tumorigenic in liver cancer cells via inhibiting YAP through AMOT.

Authors:  Guoqing Zhu; Yan Chen; Xiao Zhang; Qi Wu; Yinghui Zhao; Yuxin Chen; Fenyong Sun; Yongxia Qiao; Jiayi Wang
Journal:  Sci Rep       Date:  2017-03-21       Impact factor: 4.379

6.  Fatty acid receptor GPR120 promotes breast cancer chemoresistance by upregulating ABC transporters expression and fatty acid synthesis.

Authors:  Xue Wang; Songbing He; Yuting Gu; Qiwei Wang; Xiao Chu; Min Jin; Liang Xu; Qiong Wu; Qianjun Zhou; Bei Wang; Yanyun Zhang; Hui Wang; Leizhen Zheng
Journal:  EBioMedicine       Date:  2019-02-06       Impact factor: 8.143

Review 7.  Metabolite Sensing GPCRs: Promising Therapeutic Targets for Cancer Treatment?

Authors:  Jesús Cosín-Roger; Dolores Ortiz-Masia; Maria Dolores Barrachina; Sara Calatayud
Journal:  Cells       Date:  2020-10-23       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.